Clients

OncoSec Medical Inc.

Company Snapshot: OncoSec Medical Inc.

ONCS
Last Change Volume High Low

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.

Client News

  1. Dec 5 2019 OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
  2. Dec 5 2019 OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
  3. Dec 4 2019 OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing
  4. Dec 4 2019 OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing
  5. Dec 2 2019 OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
  6. Dec 2 2019 OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
  7. Nov 26 2019 OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference